Patents by Inventor Kevin Matthew Gardinier

Kevin Matthew Gardinier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL MCH RECEPTOR ANTAGONISTS
    Publication number: 20090170913
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein Ar1, L1, R1, q, X, R2, R3, R4, and R5 are as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.
    Type: Application
    Filed: December 16, 2005
    Publication date: July 2, 2009
    Inventors: James Peter Beck, Brian David Wakefield, Frederic Laurent Cordier, Esteban Dominguez-Manzanares, Kevin Matthew Gardinier, Peter Michael Greenen, Kenneth Allen Savin
  • NOVEL MCH RECEPTOR ANTAGONISTS
    Publication number: 20090093456
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula (1): wherein R1, Ra, Rb, R2, L1, R3, R4 and R5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.
    Type: Application
    Filed: June 8, 2007
    Publication date: April 9, 2009
    Inventors: Macklin Brian Arnold, Yen Dao, Kevin Matthew Gardinier, David Joseph Garmene, Steven James Green, Erik James Hembre, Jianliang Lu
  • CB1 MODULATOR COMPOUNDS
    Publication number: 20080287504
    Abstract: Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.
    Type: Application
    Filed: August 17, 2007
    Publication date: November 20, 2008
    Inventors: Jennifer Rebecca Allen, Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, George Stuart Gregory, Stephen Andrew Hitchcock, Paul J. Hoogestraat, Winton Dennis Jones, JR., Daryl Lynn Smith
  • Triazole derivatives as tachykinin receptor antagonists
    Patent number: 7320994
    Abstract: This application relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and its use as an inhibitor of the NK-1 subtype of tachykinin receptors, as well as a process for its preparation and intermediates therefor.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: January 22, 2008
    Assignee: Eli Lilly and Company
    Inventors: Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, Erik James Hembre, Jian Eric Hong, Louis Nickolaus Jungheim, Brian Stephen Muehl, David Michael Remick, Michael Alan Robertson, Kenneth Allen Savin
  • CB1 antagonist compounds
    Patent number: 7276516
    Abstract: Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: October 2, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jennifer Rebecca Allen, Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, George Stuart Gregory, Steven Andrew Hitchcock, Paul J. Hoogestraat, Winton Dennis Jones, Jr., Daryl Lynn Smith
  • Tachykinin receptor antagonists
    Patent number: 7179804
    Abstract: The present invention relates to selective NK-1 receptor antagonists of Formula (I); or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: February 20, 2007
    Assignee: Eli Lilly and Company
    Inventors: Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, Erik James Hembre, Jian Eric Hong, Louis Nickolaus Jungheim, Michael Alan Robertson, Kenneth Allen Savin